Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Luna Musib"'
Autor:
Andrés Cervantes, Josep Tabernero, José Baselga, Premal Patel, Yibing Yan, Kui Lin, Raymond D. Meng, Sandra M. Sanabria Bohórquez, Wai Y. Chan, Michelle Nannini, Jin Zhu, Nageshwar Budha, Luna Musib, Juan Manuel Sanchis-García, Rafael Morales-Barrera, José Alejandro Pérez-Fidalgo, Teresa Macarulla, Mafalda Oliveira, Susana Roselló, Desamparados Roda, Cristina Saura
Supplementary Table S1. IC50 values of ipatasertib on cell viability in cell lines with or without alterations in PTEN or PIK3CA. Supplementary Table S2. Percent tumor growth inhibition (%TGI) in xenograft models with or without alterations in PTEN o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e4701c0f95763c34a048939d9dd118
https://doi.org/10.1158/2159-8290.22531864
https://doi.org/10.1158/2159-8290.22531864
Autor:
Howard A. Fine, Paul S. Albert, Donald Thornton, Luna Musib, Jennifer Walling, Svetlana Kotliarova, Paul Duic, Kraig Moore, Lyndon Kim, Teri N. Kreisl
Purpose: Enzastaurin is a selective inhibitor of protein kinase C β. Prior phase I studies did not show increased drug exposures with escalating once daily administration. Limits from gastrointestinal absorption may be overcome by twice daily dosing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ba66e5356279b08adfdf4e1a9ed74d9
https://doi.org/10.1158/1078-0432.c.6516834.v1
https://doi.org/10.1158/1078-0432.c.6516834.v1
Autor:
Howard A. Fine, Paul S. Albert, Donald Thornton, Luna Musib, Jennifer Walling, Svetlana Kotliarova, Paul Duic, Kraig Moore, Lyndon Kim, Teri N. Kreisl
Supplementary Data from A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c59f4e7215f8bdd11cdb99ee355a3ab
https://doi.org/10.1158/1078-0432.22439349.v1
https://doi.org/10.1158/1078-0432.22439349.v1
Autor:
Islam Younis, Ashish Sharma, Luna Musib, Steven Zhang, Jitendra Kanodia, Vaishali Sahasrabudhe
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:946-958
Chronic kidney disease (CKD) is an important health issue that affects ~ 9.1% of the world adult population. Serum creatinine is the most commonly used biomarker for assessing kidney function and is utilized in different equations for estimating crea
Autor:
Bianca M. Liederer, Susan Wong, Vikram Malhi, Kit Wun Kathy Cheung, Justin Hanover, Luna Musib, Eunpi Cho, Rucha Sane, Emile Plise
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 378:87-95
Ipatasertib is a pan-AKT inhibitor in development for the treatment of cancer. Ipatasertib was metabolized by CYP3A4 to its major metabolite, M1 (G-037720), and was a P-gp substrate and OATP1B1/1B3 inhibitor in vitro. A phase I drug-drug interaction
Autor:
Tanya Trippett, Helen Toledano, Quentin Campbell Hewson, Arnauld Verschuur, Anne-Marie Langevin, Isabelle Aerts, Lisa Howell, Soledad Gallego, Claudia Rossig, Amy Smith, Darshak Patel, Leonardo R. Pereira, Sravanthi Cheeti, Luna Musib, Katherine E. Hutchinson, Clare Devlin, Ronald Bernardi, Birgit Geoerger
Publikováno v:
Scientia
Cobimetinib; Pediatrics; Refractory Solid Tumors Cobimetinib; Pediatria; Tumors sòlids refractaris Cobimetinib; Pediatría; Tumores sólidos refractarios Background: The MAPK pathway is an emerging target across a number of adult and pediatric tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2447a9a24c936a75a35019c279b7a964
https://hdl.handle.net/11351/8147
https://hdl.handle.net/11351/8147
Autor:
Luna Musib, Josina C. Reddy, Sravanthi Cheeti, Sandhya Girish, Jin Y. Jin, Pascal Chanu, Rene Bruno, Tong Lu, Ivor Caro, Xin Wang
Publikováno v:
Journal of Investigative Dermatology. 141:930-933
Summary Long-term use of vismodegib is associated with treatment-emergent adverse drug reactions in clinical trials of patients with locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC). Treatment interruptions have been recommende
Autor:
Ilsung Chang, Johanna C. Bendell, Raymond D. Meng, Premal Patel, Sandra M. Sanabria-Bohórquez, Daniel C. Cho, Patricia LoRusso, Matthew Wongchenko, Geoffrey I. Shapiro, Iris T. Chan, Yibing Yan, Luna Musib
Publikováno v:
Investigational New Drugs. 39:163-174
Background: This Phase Ib study explored combination dosing of the allosteric MEK1/2 inhibitor cobimetinib and the ATP-competitive pan-AKT inhibitor ipatasertib. Methods: Patients with advanced solid tumors were enrolled to two dose escalation arms,
Autor:
Manish R. Patel, Luna Musib, Paul Conkling, Andrés Cervantes, Premal Patel, Kedan Lin, Nicholas J. Vogelzang, Ari David Baron, Johanna C. Bendell, J-C. Soria, Maha Hussain, Daniel J. Maslyar, Wai Y. Chan, Josep Tabernero, N. Xu, Steven J. Isakoff, Guillem Argiles, L. R. Molife, Han Ma, Deepak Sampath, Steven Gendreau
Publikováno v:
Scientia
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Inhibidor d'AKT; Càncer avançat; Fase I Inhibidor de AKT; Cáncer avanzado; Fase I AKT inhibitor; Advanced cancer; Phase I Background This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT
Autor:
Jing Jing, Yuan Chen, Luna Musib, Jin Y. Jin, Kit Wun Kathy Cheung, Kenta Yoshida, Rucha Sane
Publikováno v:
Cancer chemotherapy and pharmacology. 89(5)
Purpose Ipatasertib, a potent and highly selective small-molecule inhibitor of AKT, is currently under investigation for treatment of cancer. Ipatasertib is a substrate and a time-dependent inhibitor of CYP3A4. It exhibits non-linear pharmacokinetics